Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Extended lead times for key components, a low order backlog at the beginning of the period and sluggish sales in the first half, and increased work hours associated with resolving issues at the acceptance stage of healthcare projects.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥1,001 million (YoY -3.8%) |
| Operating profit | ¥-32 million |
| Ordinary income | ¥-22 million |
| Profit attributable to owners of the parent | ¥-19 million |
| Net income per share | −¥14.08 |
| Equity ratio | End of the current fiscal period 83.6 / End of previous period 79.9 |
| Total assets | ¥4,643 million |
| Net assets | ¥3,883 million |
| Cash flows from operating activities | ¥75,156 thousand |
| Cash flows from investing activities | ¥-344,355 thousand |
| Cash flows from financing activities | ¥-114,564 thousand |
| Cash and cash equivalents at end of period | ¥1,346,218 thousand |
| Full-year earnings forecast | Net Sales ¥2,700 million (YoY +5.8%) / Operating profit ¥400 million (YoY +12.1%) / Ordinary income ¥420 million (YoY +6.1%) / Net income ¥300 million (YoY +5.0%) |
| Annual Dividend Forecast | ¥85 → ¥90 |
| Segment revenue | X-ray residual stress measurement systems ¥225,975 thousand (YoY -40.4%), Healthcare Equipment ¥372,159 thousand (YoY +40.7%), Optical Application and Specialized Equipment ¥403,825 thousand (YoY +1.7%) |
| Segment profit | X-ray residual stress measurement systems ¥25,879 thousand (YoY -81.0%), Healthcare Equipment ¥-11,024 thousand, Optical Application and Specialized Equipment ¥108,628 thousand (YoY +9.0%) |
| Orders received and order backlog | Orders received ¥841,861 thousand / Order backlog ¥1,683,564 thousand |
| Depreciation and amortization | ¥53,899 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on disposal of fixed assets ¥0 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not applicable / Excluded Number of companies 0 / Company name Not applicable |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 1,393,459 |
| Treasury Shares at Period-End | 25,399 |
| Factors Behind Changes in Business Performance | Extended lead times for key components, a low order backlog at the beginning of the period and sluggish sales in the first half, and increased work hours associated with resolving issues at the acceptance stage of healthcare projects. |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.There were cases where extended lead times for key components made it impossible to meet customers’ requested delivery dates; sales in the first half struggled because the order backlog at the beginning of the period was low; and resolving issues at the acceptance stage of healthcare projects took time, resulting in more work hours than initially planned.